Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Non-small Cell Lung Cancer
DRUG: Third-generation EGFR-TKI|DRUG: EGFR-TKI
PFS, Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first), 5 years
OS, Defined as the time from the start of treatment to the death of the subject due to any cause., 5 years|ORR, Defined as the proportion of subjects achieving a complete remission (CR) or partial remission (PR) among all subjects., 5 years
inclusion criteria Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history